

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Scoping

STA Upadacitinib for treating moderately to severely active ulcerative colitis

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

A stakeholder raised two potential equality issues:

- Women who would like to avoid surgery to start a family.
- For religious groups such as Muslims, for whom this condition may impact on religious practices and cause distress.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

Upadacitinib is an oral treatment, therefore would offer an alternative to surgery for those wishing to avoid surgery to start a family.

When considering the impact on religion groups, such as Muslims, the impact of treatment on their religious practices relates to [outcomes of intestinal surgery](#). Taking upadacitinib orally would not have a similar impact.

Surgery is not considered a comparator in this appraisal, and while upadacitinib may delay any potential surgery, if upadacitinib was not to be recommended, there are alternative therapeutic options.

The preliminary view is that these issues do not need addressing by the Committee, as upadacitinib provides an alternative to the treatments causing potential equality issues.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

No

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?

No

Approved by Associate Director (name): Henry Edwards

Date: 09/02/2022